Treatment with Bay 11–7082, an inhibitor of the NF-κB pathway, reduced the levels of IGF-1 secretion and the expression of IGF-1 mRNA in OFs from patients with TAO. The gene discussed is NFKB1; the disease is thromboangiitis obliterans.